Lupin Pharmaceuticals is recalling four lots of quinapril tablets because of unacceptable levels of the nitrosamine impurity, N-nitroso-quinapril, a potential carcinogen.

Nitrosamines “may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time,” the company says in a recall notice posted on the US Food and Drug Administration (FDA) website.

Lupin says it “has received no reports of illness that appear to relate to this issue.”

Quinapril is an angiotensin-converting enzyme inhibitor used to treat hypertension. Lupin stopped marketing quinapril tablets in September 2022.

The recalled product ― quinapril tablets USP 20 mg and 40 mg ― are packaged in 90-count bottles and were distributed nationwide to US wholesalers, drug chains, mail order pharmacies, and supermarkets between March 15, 2021, and September 1, 2022.

Table. Recalled Quinapril Products

Lupin is notifying customers to immediately stop distribution of the recalled product and is arranging for the affected product lots to be returned to the company.

The company is advising patients to continue taking their medication and to contact their pharmacist, physician, or healthcare professional for advice regarding an alternative treatment.

Questions regarding this recall should be directed to Inmar Rx Solutions, Inc, at (877) 538-8445 Monday to Friday between 9:00 AM to 5:00 PM EST.

Patients and physicians are also advised to report any adverse events or side effects related to the affected products to MedWatch, the US Food and Drug Administration’s Safety Information and Adverse Event Reporting program.

As reported previously by theheart.org | Medscape Cardiology, Pfizer recalled several lots of quinapril owing to the presence of the same impurity last March and again in April.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Source: Read Full Article